FOUNDER, CHIEF EXECUTIVE OFFICER, BOARD MEMBER

JohnCarlo is a molecular and cell biologist whose doctoral research at Duke University focused on developing advanced methods to measure RNA-protein interactions in their native cellular context. Through this work, he recognized that many RNA- and RBP-targeted drug programs advance without clear evidence of selective target engagement in cells, a gap that led to the founding of Ribolytix.

BOARD MEMBER, OPERATING PARTNER

Joe serves as a Board Member and Operating Partner at Ribolytix, providing hands-on guidance across early company formation, operating strategy, and capital planning. He supports business model development and organizational build-out as Ribolytix translates its patented research into a commercial offering.

SCIENTIFIC AND STRATEGIC ADVISOR -
DRUG DISCOVERY AND BIOTECH STRATEGY

Dave is a drug discovery and R&D leader with over 30 years of experience spanning academia, pharma, and biotech. His experience spans target identification, assay development, mechanism-of-action analysis, and discovery strategy, informed by senior leadership roles in large pharmaceutical organizations and advisory work with emerging biotech companies. Dr. Morris holds a PhD in Cell Biology from the University of Liverpool and serves as a Mentor in Residence with Duke New Ventures.

SCIENTIFIC AND STRATEGIC ADVISOR –
FUNCTIONAL PROTEOMICS AND TRANSLATIONAL STRATEGY

Chip is a pioneer in functional proteomics and precision medicine. He brings scientific judgment in assay design, data interpretation, and mechanistic validation, helping ensure platform data and capabilities support translational relevance and decision-making. Dr. Petricoin holds a PhD in Microbiology and has advised numerous biotechnology companies and translational research programs.

SCIENTIFIC AND STRATEGIC ADVISOR –
OPERATIONS, DRUG DISCOVERY & DEVELOPMENT

Rodrigo is a seasoned biopharmaceutical operations leader with over two decades of experience advancing drug development programs from discovery through regulatory approval in dynamic biopharma environments. He brings extensive, hands-on experience in operational strategy, CRO oversight, and program execution, with a practical understanding of how contract research organizations are leveraged to accelerate timelines, manage risk, and scale complex development programs. He holds a PhD in Biochemistry from the Hebrew University of Jerusalem.

SCIENTIFIC AND STRATEGIC ADVISOR –
BUSINESS DEVELOPMENT AND COMMERCIALIZATION

Andrew is a business development and innovation leader with over 20 years of experience helping technology-driven companies grow and scale across biotech. He brings demonstrated expertise in partnership strategy, alliance governance, M&A diligence, commercialization, and capability building, bridging scientific innovation with commercial execution. Dr. Skulan holds a PhD in Chemistry from Stanford University.

SCIENTIFIC AND STRATEGIC ADVISOR –
LICENSING AND PARTNERSHIPS

Galo brings a background in neuroscience research, preclinical drug discovery, and biopharma business development to Ribolytix. He currently supports technology out-licensing and industry collaborations for Duke University, working across life science and software intellectual property portfolios. His experience spans academic and industry drug discovery, early-stage biotech, and pharmaceutical business development, providing practical insight into translational strategy and partnership formation. He holds a BS in Microbiology and an MBA.